Thromboembolic Risk in Patients with COVID-19 Admitted to ICU in Two Teaching Hospitals in Mashhad

Document Type : Original Article(s)

Authors

1 Associate Professor, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Internal Residency, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Associate Professor of Hematology-Oncology, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 - MSc, Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Associate Professor, Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

10.48305/jims.v43.i809.0275

Abstract

Background: Thromboembolic events are a common complication in critically ill patients, and the risk is particularly elevated in patients with COVID-19, especially those admitted to intensive care units (ICUs). This study aimed to investigate the incidence of thromboembolic events and their association with clinicopathological features in patients with COVID-19 admitted to ICUs of two teaching hospitals in Mashhad.
Methods: This retrospective study included all patients with COVID-19 admitted to ICUs over a one-year period. Demographic, clinical, laboratory, and therapeutic information, including age and gender, history of thromboembolic events, underlying diseases, medications, laboratory parameters, anticoagulant therapy, and prophylactic or therapeutic dose before thromboembolic events, were extracted from patient records. Patients were divided into two groups based on the occurrence of thromboembolic events and compared and analyzed for the relevant variables.
Findings: A total of 272 patients were included in the study, of whom 15 (6%) developed thromboembolic events, with the most common type being CVA (86.7%). No statistically significant differences were observed between the two groups regarding demographic, clinical, and laboratory characteristics.
Conclusion: The incidence of thromboembolic events in patients with COVID-19 admitted to ICUs was consistent with reported ranges in other studies. The elevated risk of thromboembolic events in these patients underscores the need for intensified monitoring and implementation of preventive measures to reduce this risk.

Highlights

Sahar Ravanshad: Google Scholar 

Hassan Mehrad-Majd:  Google Scholar 

Keywords

Main Subjects

References

  1. Corman VM, Lienau J, Witzenrath M. [Coronaviruses as the cause of respiratory infections] [in German]. Internist (Berl) 2019; 60(11): 1136-45.
  2. Jackson GG, Muldoon RL. Viruses causing common respiratory infections in man. 3. Respiratory syncytial viruses and coronaviruses. J Infect Dis 1973; 128(5): 674-702.
  3. Kawana A. [SARS, MERS and coronavirus infections]. [in Japanese] Nihon Rinsho 2016; 74(12): 1967-72.
  4. Turan Civraz AZ, Duzyol I, Atli E, Caglayan C, Ozer Yurt E, Ata A, et al. Incidence of thromboembolism in COVID-19 patients in intensive care units: a retrospective cohort analysis. Cureus 2023; 15(10): e47014.
  5. Baksh M, Ravat V, Zaidi A, Patel RS. A systematic review of cases of acute respiratory distress syndrome in the coronavirus disease 2019 pandemic. Cureus 2020; 12(5): e8188.
  6. Jain U. Effect of COVID-19 on the Organs. Cureus. 2020; 12(8): e9540.
  7. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38(4 Suppl): S495-501.
  8. Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev 2021; 47: 100761.
  9. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18(6): 1421-4.
  10. Mazzeffi MA, Chow JH, Tanaka K. COVID-19 Associated Hypercoagulability: Manifestations, Mechanisms, and Management. Shock 2021; 55(4): 465-71.
  11. Zuin M, Engelen MM, Barco S, Spyropoulos AC, Vanassche T, Hunt BJ, et al. Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. Thromb Res 2022; 209: 94-8.
  12. Alavian F. Association between COVID-19 Infection and Thrombotic Stroke: A Systematic Review [in Persian]. Shefaye Khatam 2021; 10(1): 85-98.
  13. Shahjouei S, Tsivgoulis G, Farahmand G, Koza E, Mowla A, Vafaei Sadr A, et al. SARS-CoV-2 and stroke characteristics: a report from the multinational COVID-19 Stroke Study Group. Stroke. 2021; 52(5): e117-e30.
  14. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID- 19: a systematic review and meta- analysis. International Journal of Stroke. 2021; 16(2): 137-49.
  15. Lou M, Yuan D, Liao S, Tong L, Li J. Potential mechanisms of cerebrovascular diseases in COVID-19 patients. J Neurovirol 2021; 27(1): 35-51.
  16. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020; 63(3): 364-74.
  17. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan , JAMA neurology 2020; 77(6): 683- 90.
  18. Manne BK, Denorme F, Middleton EA,Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID- 19. Blood. 2020; 136(11): 1317-29.
Journal of Isfahan Medical School
Volume 43, Issue 809
1st Week, June
May and June 2025
Pages 275-282

Files

History

  • Receive Date: 16 June 2024
  • Accept Date: 26 May 2025

Share

How to cite

Statistics